EGFR and melanoma: The anticancer activity of compound C2 was found to be better than that of curcumin and anti-EGFR drugs (gefitinib and imatinib) against CNS, melanoma, ovarian, prostate, and breast cancer cell lines, it was also found as active against all the cell lines of leukemia and breast cancer cell line panels (Table 2).